Ownership and insider activity for Veracyte, Inc. (VCYT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Price
| Price | $47.67 |
| Market Cap | $3.8B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-21 | Leite John | S-Sale | 4,015 | $161K |
| 2026-09-14 | Holstein Jens | S-Sale | 5,000 | $205K |
| 2026-09-02 | Wygant Jonathan | F-InKind | 1,361 | $61K |
| 2026-09-02 | Leite John | F-InKind | 3,961 | $178K |
| 2026-09-02 | Febbo Phillip G. | F-InKind | 3,639 | $163K |
| 2026-09-04 | Febbo Phillip G. | S-Sale | 10,405 | $446K |
| 2026-09-04 | Febbo Phillip G. | S-Sale | 2,705 | $118K |
| 2026-09-02 | Chambers Rebecca | F-InKind | 3,603 | $162K |
| 2026-09-04 | Chambers Rebecca | S-Sale | 2,477 | $106K |
| 2026-09-04 | Chambers Rebecca | S-Sale | 1,175 | $51K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $59.2M | $33.9M | $78.0M | $159.3M | $349.4M | $173.2M | $154.2M | $216.5M | $239.1M | $362.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $4.0M | $24.6M | 0 | $50.4M | $50.3M |
| Receivables | $8.8M | $12.7M | $13.2M | $19.3M | $18.5M | $41.5M | $44.0M | $40.4M | $46.5M | $44.7M |
| Inventory | $3.5M | $5.3M | $3.4M | $6.8M | $4.7M | $11.2M | $14.3M | $16.1M | $21.8M | $20.5M |
| Total Current Assets | $73.6M | $53.9M | $97.0M | $187.7M | $375.7M | $243.1M | $248.6M | $285.6M | $372.3M | $488.4M |
| Property, Plant & Equipment | $11.5M | $9.7M | $8.9M | $17.7M | $16.8M | $31.1M | $30.9M | $30.9M | $71.1M | $58.8M |
| Goodwill | $1.1M | $1.1M | $1.1M | $2.7M | $2.7M | $707.9M | $695.9M | $703.0M | $745.8M | $767.2M |
| Intangible Assets | $14.1M | $13.1M | $12.0M | $65.0M | $59.9M | $202.7M | $174.9M | $88.6M | $102.3M | $89.1M |
| Total Assets | $101.0M | $78.7M | $120.6M | $275.2M | $457.2M | $1.19B | $1.16B | $1.11B | $1.30B | $1.41B |
| Accounts Payable | $2.4M | $3.9M | $2.5M | $2.3M | $3.1M | $12.4M | $11.9M | $12.9M | $8.6M | $4.6M |
| Short-term Debt | 0 | 0 | $1.4M | 0 | 0 | $1.1M | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $11.5M | $12.0M | $13.1M | $17.5M | $16.8M | $64.2M | $62.6M | $61.2M | $78.6M | $59.9M |
| Long-term Debt | $24.9M | $24.9M | $23.9M | $694,000 | $810,000 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $41.5M | $41.4M | $40.9M | $35.8M | $35.9M | $91.3M | $81.2M | $70.8M | $124.1M | $96.4M |
| Retained Earnings | -$180.1M | -$211.1M | -$234.1M | -$246.7M | -$281.6M | -$357.2M | -$393.7M | -$468.1M | -$444.0M | -$377.6M |
| Total Equity | $59.6M | $37.2M | $79.8M | $239.5M | $421.2M | $1.10B | $1.08B | $1.04B | $1.18B | $1.31B |
| Total Debt | $25.5M | $25.2M | $25.3M | $13.6M | $12.3M | $18.9M | $14.7M | $12.6M | $50.7M | $39.7M |
| Net Debt | -$33.7M | -$8.6M | -$52.7M | -$145.7M | -$337.0M | -$158.3M | -$164.1M | -$203.8M | -$238.7M | -$373.2M |
| Working Capital | $62.1M | $41.9M | $83.9M | $170.2M | $358.9M | $179.0M | $186.0M | $224.4M | $293.6M | $428.4M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 9.16 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 21.11 |
Profitability
| Return on Equity | 8.64% |
| Return on Invested Capital | 6.70% |
| Return on Assets | 7.70% |
| Gross Margin | 72.09% |
| Operating Margin | 17.03% |
| Net Margin | 20.37% |
Related companies: ADPT · IDYA · IRON · KNSA · LEGN
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of VCYT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks